Biodesix launches GeneStrat NGS, IQLung testing strategy
Jan. 28, 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Siemens launches Enhanced Liver Fibrosis test in U.S.
Jan. 26, 2022—Siemens Healthineers’ Enhanced Liver Fibrosis test is now available in the United States.
DiaSorin updates RUO Simplexa SARS-CoV-2 Variants Direct
Jan. 14, 2022—DiaSorin Molecular has released an updated version of its Simplexa SARS-CoV-2 Variants Direct assay, for research use only, to enable the detection of mutations associated with the omicron variant (B.1.1.529).
Quidel to acquire Ortho Clinical Diagnostics
Dec. 27, 2021—Quidel and Ortho Clinical Diagnostics have entered into a definitive agreement in which Quidel will acquire Ortho for $24.68 per share of common stock for a total consideration of about $6.0 billion.
Streck launches QC for sepsis
Dec. 24, 2021—Streck announced the availability of its MDx-Chex for BCID2 quality control, designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis.
Bio-Rad SARS-CoV-2 variant neutralization antibody assays
Dec. 20, 2021—Bio-Rad Laboratories launched the Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only.
Siemens SARS-CoV-2 testing portfolio detects omicron variant
Dec. 15, 2021—Siemens Healthineers has announced that the company’s SARS-CoV-2 tests are designed to detect the SARS-CoV-2 omicron variant.
Seegene unveils PCR test that IDs omicron, VOCs in one tube
Dec. 13, 2021—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only.
Roche AI-based digital pathology algorithms for breast cancer
Dec. 9, 2021—Roche announced the launch of three research use only automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2) image analysis for breast cancer.
SeptiCyte Rapid receives 510(k) clearance
Dec. 3, 2021—Biocartis announced that the FDA granted 510(k) clearance for its SeptiCyte Rapid test, which was developed under partnership with Immunexpress.